002589 Realcan Pharmaceutical Group
- 2.46
- -0.10-3.91%
Realcan Pharmaceutical Group News
Ruikang Pharmaceutical (002589.SZ) plans to pay 0.13 yuan for every 10 shares in 2023, excluding interest on June 4
Zhitong Finance App News, Ruikang Pharmaceutical (002589.SZ) announced that in 2023, the company plans to distribute 0.13 yuan (tax included) to all shareholders for every 10 shares. The share registration date for this equity distribution is June 3, 2024, and the ex-dividend date is June 4, 2024.
Ruikang Pharmaceutical (002589.SZ) announced first-quarter results, net profit of 15.169 million yuan, a decrease of 28.31%
Ruikang Pharmaceutical (002589.SZ) released its report for the first quarter of 2024, achieving 20 operating income during the reporting period...
Benign Growth For Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Underpins Stock's 30% Plummet
To the annoyance of some shareholders, Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) shares are down a considerable 30% in the last month, which continues a horrid run for the company. The d
Further Weakness as Realcan Pharmaceutical Group (SZSE:002589) Drops 12% This Week, Taking Five-year Losses to 60%
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example the Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) share price dr
Ruikang Pharmaceutical (002589.SZ): 2023 pre-profit of 20 million yuan to 30 million yuan
Gelonghui, January 30 | Ruikang Pharmaceutical (002589.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 20 million yuan to 30 million yuan, turning a year-on-year loss into a profit; net profit loss after deducting non-recurring profit and loss was 130 million yuan to 190 million yuan, a decrease of 79.52%-85.98% compared to the same period last year; basic earnings per share were 0.0133 yuan/share to 1990.00.0/share. The main reason why the 2023 results turned a loss into a profit compared to the same period of the previous year: the disposal of subsidiaries affects investment income and fair value
Ruikang Pharmaceutical (002589.SZ) received a warning letter from the Shandong Securities Regulatory Bureau
Ruikang Pharmaceutical (002589.SZ) announced that the company received “On Ruikang Pharmaceutical Group Shares...” issued by the Shandong Securities Regulatory Bureau
Does Realcan Pharmaceutical Group (SZSE:002589) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
Ruikang Pharmaceutical (002589.SZ) released first-half results, net profit of 306.673 million yuan, a year-on-year decrease of 48.01%
Ruikang Pharmaceutical (002589.SZ) released the 2023 semi-annual report, and the company's revenue was 4,080 billion yuan...
Ruikang Pharmaceutical (002589.SZ): There are currently no marketing plans for Ma'anshan Jingquan Chinese Medicine tablets
Glonghui, August 21丨An investor asked Ruikang Pharmaceutical (002589.SZ), “Please tell me when will Jingquan Traditional Chinese Medicine, a subsidiary of your company, resume listing.” Ruikang Pharmaceutical replied that the company's holding subsidiary, Ma'anshan Jingquan Chinese Medicine Tablet Co., Ltd. currently has no plans to go public.
Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Surges 7.1%; Retail Investors Who Own 58% Shares Profited Along With Insiders
Key Insights The considerable ownership by retail investors in Realcan Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy A total of 25 inve
Realcan Pharmaceutical Group (SZSE:002589) Stock Falls 7.8% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish catastrophic capital loss on anyone. Imagine if you held Realcan Pharmaceutical Group C
Realcan Pharmaceutical Group Co., Ltd.'s (SZSE:002589) Market Cap up CN¥404m Last Week, Benefiting Both Individual Investors Who Own 59% as Well as Insiders
A look at the shareholders of Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company w
Realcan Pharmaceutical Group Co., Ltd.'s (SZSE:002589) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Realcan Pharmaceutical Group's (SZSE:002589) stock is up by a considerable 9.4% over the past week. But the company's key financial indicators appear to be differing across the board and that makes
Is Realcan Pharmaceutical Group (SZSE:002589) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' When we thi
Investors five-year losses continue as Realcan Pharmaceutical Group (SZSE:002589) dips a further 8.4% this week, earnings continue to decline
Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) shareholders should be happy to see the share price up 11% in the last quarter. But spare a thought for the long term holders, who have held the
Returns On Capital Signal Tricky Times Ahead For Realcan Pharmaceutical Group (SZSE:002589)
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secon
How Much Of Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) Do Insiders Own?
The big shareholder groups in Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders o
Realcan Pharmaceutical Group (SZSE:002589) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Why Realcan Pharmaceutical Group's (SZSE:002589) Shaky Earnings Are Just The Beginning Of Its Problems
The subdued market reaction suggests that Realcan Pharmaceutical Group Co., Ltd.'s (SZSE:002589) recent earnings didn't contain any surprises. We think that investors are worried about some weakness
Realcan Pharmaceutical Group Co., Ltd.'s (SZSE:002589) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/E Ratio
Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) shares have had a horrible month, losing 35% after a relatively good period beforehand. Instead of being rewarded, shareholders who have alread
Analysis
Price Target
No Data
